Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs.

Ocio EM, Mateos MV, San-Miguel JF.

Expert Opin Investig Drugs. 2012 Aug;21(8):1075-87. doi: 10.1517/13543784.2012.691164. Epub 2012 May 24. Review.

PMID:
22621161
2.

Novel generation of agents with proven clinical activity in multiple myeloma.

Mateos MV, Ocio EM, San Miguel JF.

Semin Oncol. 2013 Oct;40(5):618-33. doi: 10.1053/j.seminoncol.2013.07.005. Review.

PMID:
24135407
3.

Novel immunomodulatory compounds in multiple myeloma.

Saini N, Mahindra A.

Expert Opin Investig Drugs. 2013 Feb;22(2):207-15. doi: 10.1517/13543784.2013.749235. Epub 2012 Dec 25. Review.

PMID:
23265189
4.

Emerging biological insights and novel treatment strategies in multiple myeloma.

Gentile M, Recchia AG, Mazzone C, Morabito F.

Expert Opin Emerg Drugs. 2012 Sep;17(3):407-38. doi: 10.1517/14728214.2012.713345. Review.

PMID:
22920042
5.

Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.

Vallet S, Witzens-Harig M, Jaeger D, Podar K.

Expert Opin Pharmacother. 2012 Mar;13(4):473-94. doi: 10.1517/14656566.2012.656091. Epub 2012 Feb 13. Review.

PMID:
22324734
6.

Immunomodulatory drugs in multiple myeloma.

Andhavarapu S, Roy V.

Expert Rev Hematol. 2013 Feb;6(1):69-82. doi: 10.1586/ehm.12.62. Review.

PMID:
23373782
7.

Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.

Morgan G.

Blood Rev. 2010 Nov;24 Suppl 1:S27-32. doi: 10.1016/S0268-960X(10)70006-0.

PMID:
21126634
8.

The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.

Moreau P.

Semin Hematol. 2012 Jul;49 Suppl 1:S33-46. doi: 10.1053/j.seminhematol.2012.05.004.

PMID:
22727391
9.
10.

Future directions in immunomodulatory therapy.

Lonial S.

Med Oncol. 2010 Jun;27 Suppl 1:S62-6. doi: 10.1007/s12032-009-9376-8. Epub 2009 Dec 11. Review.

PMID:
20012563
11.

[Triplets therapy for the patients of multiple myeloma].

Ishida T.

Nihon Rinsho. 2013 Sep;71(9):1691-6. Review. Japanese.

PMID:
24205736
12.

The potential of proteasome inhibitors in cancer therapy.

Sterz J, von Metzler I, Hahne JC, Lamottke B, Rademacher J, Heider U, Terpos E, Sezer O.

Expert Opin Investig Drugs. 2008 Jun;17(6):879-95. doi: 10.1517/13543784.17.6.879 . Review.

PMID:
18491989
13.

Bortezomib for multiple myeloma.

Popat R, Joel S, Oakervee H, Cavenagh J.

Expert Opin Pharmacother. 2006 Jul;7(10):1337-46. Review.

PMID:
16805719
14.

Proteasome inhibitor therapy in multiple myeloma.

Chauhan D, Hideshima T, Mitsiades C, Richardson P, Anderson KC.

Mol Cancer Ther. 2005 Apr;4(4):686-92. Review.

15.

Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.

Castelli R, Cannavò A, Conforti F, Grava G, Cortelezzi A.

Immunopharmacol Immunotoxicol. 2012 Oct;34(5):740-53. doi: 10.3109/08923973.2012.658921. Epub 2012 Mar 9. Review.

PMID:
22401643
16.

Lenalidomide and thalidomide: mechanisms of action--similarities and differences.

Anderson KC.

Semin Hematol. 2005 Oct;42(4 Suppl 4):S3-8. Review.

PMID:
16344099
17.

Treatment of relapsed and refractory multiple myeloma in the era of novel agents.

van de Donk NW, Lokhorst HM, Dimopoulos M, Cavo M, Morgan G, Einsele H, Kropff M, Schey S, Avet-Loiseau H, Ludwig H, Goldschmidt H, Sonneveld P, Johnsen HE, Bladé J, San-Miguel JF, Palumbo A.

Cancer Treat Rev. 2011 Jun;37(4):266-83. doi: 10.1016/j.ctrv.2010.08.008. Epub 2010 Sep 21. Review.

PMID:
20863623
18.

Novel proteasome inhibitors to overcome bortezomib resistance.

Ruschak AM, Slassi M, Kay LE, Schimmer AD.

J Natl Cancer Inst. 2011 Jul 6;103(13):1007-17. doi: 10.1093/jnci/djr160. Epub 2011 May 23. Review.

PMID:
21606441
19.

Proteasome inhibitors therapeutic strategies for cancer.

D'Alessandro A, Pieroni L, Ronci M, D'Aguanno S, Federici G, Urbani A.

Recent Pat Anticancer Drug Discov. 2009 Jan;4(1):73-82. Review.

PMID:
19149689
20.

Integration of novel agents into treatment of myeloma.

Lee AI, Munshi NC.

Clin Lymphoma Myeloma. 2007 Aug;7 Suppl 5:S215-21. Review.

PMID:
17877847

Supplemental Content

Support Center